Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Mesothelioma, Malignant 2Melanoma 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Primary Myelofibrosis 1PD-L1 Positive Mutation Tumor 1Metastatic Solid Tumors 1Mesothelioma 1Malignant Solid Tumour 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

ruxolitinib 1avelumab 1Pemetrexed 1Imatinib Mesylate 1Fentanyl 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × avelumab × Other solid neoplasm × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡